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ABSTRACT
Introduction Cardio‐ankle vascular index (CAVI) is a 
new marker of arterial stiffness (AS) that can assess 
vascular wall stiffness in the aorta, femoral artery and 
tibial artery. CAVI is less affected by blood pressure at 
the time of measurement than the gold standard method 
(carotid- femoral pulse wave velocity (PWV)). Our group 
has developed a device called VOPITB (Velocidad Onda 
de Pulso Índice Tobillo Brazo) that uses the oscillometric 
method and easily and accurately measures the PWV in 
the arms and legs separately, allowing new AS indices to 
be studied. This article describes the research protocol to 
determine CAVI using VOPITB and to validate the device 
against a reference device (VaSera VS-1500) and assess 
its clinical utility.
Methods and analyses A cross- sectional, descriptive and 
observational study will be conducted. In all, 120 subjects 
(a minimum of 40% of subjects from any one gender) 
will be evaluated. CAVI will be determined from the 
measurement by VOPITB and VaSera VS-1500. For each 
subject, the average of the three readings taken with each 
device will be calculated. The Bland- Altman plot will be 
used to determine whether any bias exists in the data—
that is, a tendency of the size of the difference to vary with 
the mean. The participants will be divided roughly equally 
between the following age bands: <30, 30–60 and >60 
years.
Ethics and dissemination The study has been approved 
by the ethics committee of the Hospital San Pedro de 
Alcántara, Cáceres, Spain. The participants will be required 
to sign an informed consent form before inclusion in the 
study, in accordance with the Declaration of Helsinki 
and WHO standards for observational studies. The 
dissemination plan of the research study results will be 
through presentations in relevant national and international 
conferences and scientific publications in peer- reviewed 
journals.
Trial registration number NCT04303546.
INTRODUCTION
Arterial stiffness (AS) is usually related to the 
structural and functional properties of large 
arteries, and it is considered a predictor of 
cardiovascular events.1 2 Furthermore, AS 
is likely to predate hypertension and target 
organ damage, with important implications 
for the early identification of individuals at 
high risk of cardiovascular disease (CVD).3 
The elastic wall properties of large arteries 
are measured by carotid- femoral pulse wave 
velocity (cfPWV), which is considered the 
gold standard for AS assessment.1 4 5 However, 
the high cost of the commercial equipment 
available on the market (SphygmoCor, 
Complior), the discomfort for some patients 
when exposing the inguinal area and the time 
needed to perform the examination limit its 
routine use primarily to research applica-
tions. Moreover, the difficulty in locating the 
carotid and femoral pulses during measure-
ments makes the equipment highly operator- 
dependent.6–8 To simplify this technique and 
consider that any part of the body could be 
appropriate to assess AS, new methods have 
been proposed in Japan by measuring PWV 
in peripheral arteries: cardio- ankle vascular 
index (CAVI)9 and brachial- ankle pulse wave 
velocity (baPWV).10
CAVI is a new marker of AS9 based on the 
stiffness parameter β11 and Bramwell- Hill 
Strengths and limitations of this study
 ► VOPITB (Velocidad Onda de Pulso Índice Tobillo 
Brazo) is a new oscillometric device that measures 
the pulse wave velocity (PWV) in the arms and legs 
separately.
 ► Cardio‐ankle vascular index (CAVI) is an alternative 
method to assess arterial stiffness and overcomes 
some disadvantages of the gold standard method, 
that is, carotid- femoral PWV.
 ► This study will validate CAVI using VOPITB against 
a reference device (VaSera VS-1500) and assess its 
clinical use.
 ► Incorporating CAVI into VOPITB functions would 
complement the diversity of variables that allow the 
estimation of arterial stiffness.
 ► Limitations include that the inclusion of muscular 
arteries may contribute little to the prognostic value 
of CAVI.
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formula.12 CAVI can quantitatively assess vascular wall 
stiffness in the aorta, femoral artery and tibial artery by 
measuring the increase in AS observed from end‐dias-
tole to end‐systole.9 CAVI is less affected by blood pres-
sure (BP) at the time of measurement compared with 
cfPWV.13 14 The measurement method is also simplified 
using BP cuffs located in both arms and ankles and 
a microphone on the chest. In addition, it is mainly 
operator- independent14 with good reproducibility.15 A 
recent meta- analysis found an association between CAVI 
and incident CVD.16
Our group has developed a device called VOPITB 
(Velocidad Onda de Pulso Índice Tobillo Brazo),17 which 
uses the oscillometric method to easily and accurately 
measure PWV in the arms and legs separately, allowing 
new AS indices to be studied (sum, difference, ratio, 
baPWV and CAVI). For example, the difference in PWV 
in the leg and the arm is correlated with the quantifica-
tion of coronary calcium,18 and the sum of PWVs from all 
the limbs is associated with cardiovascular risk.17 More-
over, the clinical use of baPWV measured by VOPITB is 
similar to that measured by VaSera VS-1500.19 Because 
VOPITB can independently measure PWV in each limb, 
it is possible to calculate CAVI. Incorporating CAVI into 
VOPITB functions would complement the diversity of 
variables that allow the estimation of AS. This article 
describes the research protocol to determine CAVI using 
VOPITB and to validate the device against a reference 
device (VaSera VS-1500) and assess its clinical use.
METHODS AND ANALYSIS
The experimental protocol was developed according 
to the recommendations of the ARTERY Society guide-
lines for the validation of non- invasive haemodynamic 
measurement devices.20
Study setting and design
This cross- sectional, descriptive and observational study 
will be conducted at the Hospital Universitario San Pedro 
de Alcántara of Cáceres and Centro de Salud Zona Centro 
of Cáceres (Spain). The time estimated for this project is 
8 months.
Sample size and study population
The sample size has been calculated so that a difference 
between CAVI values obtained from the measurement 
of both devices, VOPITB and VaSera VS-1500, will be up 
to 0.8 points compared with the CAVI reference values 
for the Spanish adult population.21 The base parameters 
used to calculate the sample size were as follows: SD of 
CAVI measured by VaSera VS-1500 and VOPITB: 1.44; 
mean difference between CAVI measurements: 0.8; CI: 
95%; and power: 80%. Thus, the estimated sample size 
was calculated as 102 patients. In addition, to compen-
sate for possible incomplete data sets from patients who 
could withdraw or fail to complete the study, 20% were 
added. Finally, a total of 120 subjects (a minimum of 40% 
of subjects from each gender) will be evaluated according 
to the following criteria:
 ► <30 years (40 subjects).
 ► 30–60 years (40 subjects).
 ► 60 years (40 subjects).
Subjects <30 years of age will be recruited from among 
students of Extremadura University. Subjects 30–60 years 
of age will be selected from among hospital and university 
workers. Finally, subjects >60 years of age will be recruited 
from among primary care patients at the health centre. 
The participants will be required to sign an informed 
consent form before inclusion in the study, in accordance 
with the Declaration of Helsinki and WHO standards for 
observational studies.22
Inclusion criteria
Subjects ≥18 years of age who agree to participate in the 
study and do not meet any of the exclusion criteria.
Exclusion criteria
 ► History of CVD (ischaemic heart disease, stroke or 
peripheral artery disease (PAD)).
 ► Atrial fibrillation or other cardiac rhythm disorders.
 ► Pacemaker dependent.
 ► Impalpable arterial pulse at the site of measurement.
 ► PAD: either intermittent claudication with an ankle- 
brachial index (ABI) less than 0.9 or high, or previous 
vascular intervention or limb amputation for PAD.
 ► Aortic valve diseases and aortic diseases.
 ► Subjects with haemodialysis.
 ► Pregnancy.
 ► Terminal condition.
 ► Age <18 years.
Patient and public involvement
Patients and/or the public were not involved in the 
design, conduction, reporting or dissemination plans of 
this research.
Variables and measurement instruments
Information containing general and variable data, such as 
age, gender, occupation, family history of CVD, cardiovas-
cular risk factors (diabetes, hypertension, dyslipidaemia, 
obesity, chronic renal failure and tobacco consumption), 
alcohol consumption and medications and drugs used, 
will be recorded. We will also collect the start date and 
doses of medications, namely, antihypertensive, antidia-
betic and antiplatelet agents; anticoagulants; and lipid- 
lowering drugs.
Parameters such as weight, height, body mass index 
(BMI), waist circumference, heart frequency and BP will 
be determined during physical examination. Height will 
be measured using a Harpenden stadiometer, and weight 
will be measured using a biomedical precision balance 
(Seca 770; Medical Scale and Measurement Systems, 
Birmingham, UK). Both measurements will be deter-
mined only when the participants will be wearing light 
clothing and no shoes. The BMI will be calculated as the 
weight in kilograms divided by the square of the height 
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value in metres (kg/m2). The waist circumference will be 
measured using a flexible graduated measuring tape with 
the patient in the standing position without clothing. BP 
will involve three measurements of systolic BP (SBP) and 
diastolic BP (DBP), and its value will be calculated as the 
mean values of the last two performed using a validated 
OMRON model HEM-907 sphygmomanometer (Omron 
Healthcare, Kyoto, Japan) according to the recommen-
dations of the European Society of Hypertension.23 ABI 
will be performed oscillometrically using VOPITB and 
VASERA.
CAVI measurement
The physical examination of the volunteers will be 
performed early in the morning. Subjects will be in the 
fasting condition and will be asked not to smoke for 1 hour 
before examination. They will rest in the lying position 
for at least 10 min before the measurement. All examina-
tions will be conducted at least 12 hours after taking any 
vasoactive drugs. The values of CAVI will be determined 
from the measurements by VOPITB and VaSera VS-1500 
(FukudaDenshi Co.). Six sequential recordings will be 
made by two operators, alternating the devices between 
recordings (three with VOPITB and three with VaSera 
VS-1500). The order of the device used in the measure-
ments will also be alternated between subjects (table 1). 
The measurements will be taken 2–3 min apart to avoid 
reactive hyperaemia.
CAVI integrates information about the elasticity 
of blood vessels and represents a novel parameter of 
vascular stiffness that does not depend on BP.14 The math-
ematical expression to calculate CAVI values is described 
elsewhere9 14 and is mainly based on substituting the 
stiffness parameters β and PWV in the following equa-
tion: β=2ρ×1/(SBP– DBP)×ln (SBP/DBP)×PWV2, where 
ρ is the blood density and PWV is the heart- ankle PWV 
(haPWV) measured between the origin of the aorta and 
the tibial artery at the ankle. The mean coefficient of vari-
ation of CAVI is <5%, which is small enough for clinical 
use. Previous studies confirmed that CAVI has favour-
able intraobserver reproducibility at different times and 
interobserver reproducibility with different operators.9 
The CAVI values, according to age and gender, are clas-
sified as normal (CAVI<8), borderline (8≤CAVI<9) and 
abnormal (CAVI≥9).
PWV measurement to calculate CAVI will be performed 
by VOPITB according to a previously described tech-
nique.17 Briefly, four cuffs are positioned on the two arms, 
near the elbow flexion crease, and on the two legs, close 
to the ankles. This device performs all functions automat-
ically, including the cuffs inflating and recording pulse 
waves with an incorporated oscillometric sensor. The 
haPWV (m/s) is estimated using the following equation: 
heart- ankle length (Lha)/time. Time is the pulse transit 
time of the pulse wave from the origin of the aorta (peak 
of the R wave in lead II of an electrocardiographic record 
incorporated in the system) to its arrival at each of the 
extremities (the cuff placement). The Lha will be calcu-
lated by applying the next mathematical height- based 
formula: Lhl=0.8129×height (cm)+12.328. This measure-
ment method was validated by VOPITB in the Spanish 
population24 and is also validated by VaSera VS-1500. 
Because VOPITB can measure the haPWV in each 
limb, CAVI can be determined. The equation to calcu-
late CAVI using the VOPITB device is described above 
(CAVI=2ρ×1/(SBP–DBP)×ln (SBP/DBP)×haPWV2). The 
SI unit of BP will be used to convert haPWV to CAVI by 
VOPITB. Other CAVI measurements will be performed 
using VaSera VS-1500 according to the manufacturer’s 
instructions.9 Cuffs will be fitted to the size of the arms 
and ankles of the patients. Electrodes will be attached 
to the two arms and two ankles, and a microphone for 
cardio- phonogram measurements will be fixed with 
double- sided tape over the sternum in the second inter-
costal space. CAVI measurements will be considered valid 
only when obtained during at least three consecutive 
heartbeats.14
Statistical analysis
For each subject, the average value of the three readings 
taken with each device will be calculated. The Bland- 
Altman plot will be used to determine whether any bias 
exists in the data—that is, a tendency of the size of the 
difference to vary with the mean.20 The plot will show 
mean and ±2 SD. Ninety- five percent of the readings will 
lie between ±2 SD of the mean.
Continuous variables will be expressed as mean±SD 
for the case of normal distribution or as medians (IQR) 
for asymmetric distribution, and the categorical vari-
ables will be expressed as frequencies and percentages. 
The Kolmogorov- Smirnov test will be used to determine 
whether the continuous variables follow a normal distri-
bution. The relationship of quantitative variables to each 
other will be tested using Pearson’s or Spearman’s correla-
tion, as appropriate. Analysis of the difference of means 
between the continuous variables of two categories will be 
carried out using Student’s t- test or the Mann- Whitney U 
test, as appropriate; categorical variables will be analysed 
using χ² test. To evaluate the relationship between the 
continuous variables of more than two categories, anal-
ysis of variance and least significant difference test will be 
used in post hoc tests. The Kruskal- Wallis test will be used 
in cases where the variables are not normally distributed. 
Table 1 Order of measurement for two sequential subjects
Subject 1 Subject 2
VOPITB, observer A VaSera VS-1500, observer A
VaSera VS-1500, observer B VOPITB, observer B
VOPITB, observer A VaSera VS-1500, observer A
VaSera VS-1500, observer B VOPITB, observer B
VOPITB, observer A VaSera VS-1500, observer A
VaSera VS-1500, observer B VOPITB, observer B
Adapted from Wilkinson et al.20
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A value of p<0.05 will be considered statistically signifi-
cant. The analyses will be performed using SPSS V.24.0 
for Windows (SPSS).
ETHICS AND DISSEMINATION
The study designs were approved by the ethics committee 
of the Hospital San Pedro de Alcántara, Cáceres, Spain. 
The participants will be required to sign an informed 
consent form before inclusion in the study, in accordance 
with the Declaration of Helsinki and WHO standards for 
observational studies.22 The confidentiality of the subjects 
will be guaranteed at all times in accordance with the 
provisions of current legislation on personal data protec-
tion (15/1999 of 13 December Protection of Personal 
Data Official Law), and the conditions will be contem-
plated by Act 14/2007 on biomedical research.
The dissemination plan of the research study results 
will be through presentations in relevant national and 
international conferences and scientific publications in 
peer- reviewed journals.
DISCUSSION
CAVI is an alternative method to assess AS and overcomes 
some disadvantages of the gold standard method, that 
is, cfPWV. For example, it is easier to use, overcomes the 
problem of the acquisition of good carotid and femoral 
artery pulses, which is usually operator- dependent, and 
is sometimes challenging for clinical staff.25 In addi-
tion, CAVI is more comfortable for patients because the 
inguinal area is not exposed during the examination26 
and the time needed to generate CAVI is usually less than 
that for the cfPWV measurements. Furthermore, cfPWV 
does not include the ascending aortic segment, which 
confirms the earliest changes during arterial ageing and 
disease.16 By contrast, CAVI reflects the stiffness from 
the ascending aorta to the ankle arteries and may be a 
comprehensive marker of systemic AS.27 Other potential 
advantages include that CAVI has low operator depen-
dency and is less affected by BP at the time of measure-
ment than cfPWV.14 Moreover, CAVI may have higher 
reproducibility than PWV in several vascular beds.9 
Currently, VaSera VS-1500 is the only commercial device 
that calculates CAVI. It is widely used in Asian countries 
and scarcely used in Europe (probably due to its high 
cost).
VOPITB calculates the PWV in the extremities using 
the oscillometric method, allowing the analysis of new 
PWV indices.17 It is simple to use and can correctly 
stratify patients according to their vascular risk.17–19 The 
AS variables provided by VOPITB make it a promising 
device for routine clinical practice in vascular risk eval-
uation in a large population. Incorporating CAVI into its 
performance (an AS variable of contrasted prognostic 
value) would complement the information provided by 
VOPITB and would make it a competitive device in the 
field of AS assessment. VOPITB is a European device, 
and its price will be lower than that of VaSera VS-1500. In 
addition, VOPITB determines more AS parameters than 
VaSera; thus, it will provide a more thorough evaluation 
of patients.
Study limitations
The inclusion of AS of leg arteries may be considered a 
caution of CAVI because elastic artery stiffness, but not 
muscular artery stiffness, seems to be independently asso-
ciated with cardiovascular risk.4 Therefore, the inclusion 
of muscular arteries may contribute little to the prognostic 
value of CAVI. However, the practical implications of this 
issue in CVD risk assessments remain unclear and require 
future studies. In addition, baPWV (a parameter of AS 
including leg arteries) predicts CVD risk independently 
of traditional risk factors.28 Finally, the measurements 
used in this validation study will not be against an invasive 
method; however, PWV measured by VOPITB has already 
been validated with invasive techniques.17
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